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INTRODUCTION
The prototypic antimetabolite drug hydroxyurea (HU) has been used to treat a variety of human cancers including chronic myelogenous leukemia, head and neck cancer, and others (Hehlmann 2003, Shewach and Lawrence 2007) . Its primary anticancer and cellular target is ribonucleotide reductase (RNR), which reduces ribonucleotides to their corresponding deoxy forms to supply dNTPs for DNA replication and repair (Reichard and Ehrenberg 1983, Xue et al. 2003) . The human RNR is composed of the hRRM1 and hRRM2 subunits (Reichard and Ehrenberg 1983, Xue et al. 2003) . Following a genotoxic stimulus, an alternate RNR enzyme, which is composed of hRRM1 and p53R2 (a homologue of hRRM2 transactivated by the tumor suppressor protein p53) is induced to supply dNTPs for DNA repair (Shao et al. 2004 ). Within cells, HU inhibits both types of RNR (Shao et al. 2004 ) through generating free radicals via oxidative transformation (Young and Hodas 1964 ) that quenches free-radical mediated catalysis (Reichard and Ehrenberg 1983) . Blocking this signaling can arrest DNA replication and reduce cell growth (Shewach and Lawrence 2007) . However, therapeutically, HU is limited by its short half-life and problematic side effects, most notably myelosuppression, and gastrointestinal and dermatologic effects (Platt 2008) .
COH29 is an RNR inhibitor that demonstrates promise as an anti-cancer agent and is currently in preclinical development at City of Hope Cancer Center. COH29 is an aromatically substituted thiazole compound that occupies a structurally conserved ligand-binding pocket on the hRRM2 subunit located at the hRRM1/hRRM2 interface, thereby inhibiting hRRM1/hRRM2 assembly, effectively inhibiting RR activity (Zhou et al. 2013) . In vitro COH29 inhibits the proliferation of multiple human cancer cell lines with an IC 50 less than 10 µM in most cases. Treatment of cancer cells with COH29 led MOL #94987 to a dose-dependent S-phase arrest, induction of apoptosis, and cell death (Zhou et al. 2013) . One major advantage of COH-29 over other RR inhibitors in development, such as 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine, 3-AP), is that it does not appear to be an iron chelator, reducing the potential side effects.
In response to DNA damage numerous DNA-repair pathway proteins collectively act to restore DNA continuity and genomic integrity (Helleday et al. 2008) . Among these different repair pathways, base-excision repair (BER) and nucleotide-excision repair (NER) are both involved in the removal of lesions and their replacement with short stretches of DNA. The continuing presence of single strand breaks during DNA replication will lead to stalled replication forks, whose resolution recombination (HR) or non-homologous end joining (NHEJ) repair which is responsible for DNA DSBs (doublestrand breaks) (Moeller et al. 2009 , Gottipati et al. 2010 . The biochemical processes of HR are mediated by multiple conserved factors including the essential recombinase RAD51, tumor suppressors BRCA1, and BRCA2 (Curtin 2012).
The efficacy of DNA-damaging drugs is highly influenced and modulated by cellular DNA repair capacity (Helleday et al. 2008) . Indeed, small-molecule inhibitors of DNA repair have been combined with conventional chemotherapy drugs in preclinical studies (Miknyoczki et al. 2003) , indicating that the DNA repair machinery is a promising target for novel cancer treatments.
Herein we report that COH29 exhibits enhanced cytotoxicity in BRCA1-deficient HCC1937 cells compared with HCC1937+BRCA1 cells accompanied by significant DNA DSB marker (γH2AX) accumulation in the BRCA1-defective cells, suggesting BRCA1 prevents prolonged presence of DSBs. In addition, we also found that COH29 reduced This article has not been copyedited and formatted. The final version may differ from this version. NHEJ repair efficiency in a concentration-dependent manner. In the setting of the BRCA1-defective HCC1937 cells, which we also show are HR-deficient, this inhibition of NHEJ by COH29 dramatically reduced repair of DNA lesions. Indicative of this is that after COH29 treatment fewer Rad51 nuclear foci were observed in HCC1937 than in HCC1937+BRCA1 cells. In addition, our microarray results revealed that COH29 downregulated various DNA repair genes. These data suggest defective HR and NHEJ DNA repair pathways may contribute to the cytotoxicity of COH29 in BRCA1-deficient cells, and as a corollary that BRCA1 status plays a central role in determining the cytotoxicity of COH29 in cancer cells.
This article has not been copyedited and formatted. The final version may differ from this version. 
MATERIALS & METHODS
Cell lines
All cell lines were acquired from the American Type Culture Collection (Manassas, VA, USA), and were maintained in RPMI 1640 medium (Mediatech) with 10% fetal bovine serum, 2 mM glutamine, and 100 U of penicillin and 100 µg of streptomycin per ml of 
Immunofluorescence
Immunofluorescence experiments on HCC1937 and HCC1937+BRCA1 cells were conducted as described previously (Chung et al. 2012 , Hu et al. 2014 
Subcellular Fractionation and Immunoblotting
For details of the subcellular fractionation, cells were trypsinized and washed with cold PBS solution twice. After centrifugation at 1,200g for 5 min, cells were incubated in buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA) containing 0.2% Nonidet P-40 (NP-40), supplemented with protease inhibitors (5 μ g/ml each of pepstatin, leupeptin, and aprotinin) and phosphatase inhibitors on ice for 5 min. Following centrifugation at 1,000g for 5 min, the supernatant was collected (i.e., cytoplasmic fraction) and pellets were washed with the same buffer twice. The washed samples were extracted for 40 min on ice with fractionation buffer containing 0.5% NP-40 for nuclear fraction. All the samples were sonicated and clarified by centrifugation at 16,000g for 15 min. Protein concentrations of all fractions were determined with Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA). Immunoblotting was performed as described previously (Chung et al. 2012 , Hu et al. 2014 ).
Cytotoxicity and Viability Assays
This article has not been copyedited and formatted. The final version may differ from this version. Cytotoxicity was assessed by Digital Imaging Microscopy System (DIMSCAN) detection (Keshelava et al. 2005 ).
Viability was assessed using MTS [(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)] as previously described. 
DNA repair assays
Reporter cell lines for GFP-based DNA damage repair assays were established by stable transfection of HCC1937 and HCC1937+BRCA1 cells with the pimEJ5GFP
reporter plasmid for NHEJ (Bennardo et al. 2008 ) and the pHPRT-DRGFP reporter plasmid for HR (Pierce et al. 2001) respectively, and selected with 0.3 μ g/ml puromycin.
The resultant HCC1937-EJ5GFP and HCC1937+BRCA1-DRGFP cells were first pretreated with COH29 for 24h, and then transiently transfected with a predetermined mixture of pCBA-Scel plasmid to express I-Scel endonuclease and a plasmid to express 
siRNA interference assay
This article has not been copyedited and formatted. The final version may differ from this version. The construction of the anti-human BRCA1 siRNA-expressing plasmid was performed as described (Un et al. 2006 ) using previously published anti-human BRCA1 siRNA sequences (5'-UCACAGUGUCCUUUAUGUA-3" and 5'-UACAUAAAGGACACUGUGA-3'). In each case, the annealed oligonucleotide duplex encoding the siRNA was subcloned into the expression vector psiRNA-hH1zeo (InvivoGen, San Diego, CA, USA)
to express under the control of the RNA polymerase III-dependent H1 RNA promoter.
Cells were transfected with the indicated plasmid at equimolar concentration via electroporation.
Zebrafish genotoxicity assay
Zebrafish (Danio rerio) were obtained from zebrafish Core facility of Taipei Medical
University and maintained at 28 o C on a 14h light/10h dark cycle. Embryos were incubated at 28 o C and different developmental stages were determined as described (Westerfield 1993) . Fifteen wild-type embryos each were treated with concentrations of HU (0, 5, 10, 20, 50 mM) or COH29 (0, 10, 20, 50, 100 μ M) at 20 hpf (hours postfertilization) to evaluate the mutagenic effect. Treated embryos were observed at 2, 3, 4, 5 and 6 dpf (days post-fertilization). At 6 dpf, the percentage of fish exhibiting developmental abnormalities and the survival rate was determined. Embryos were observed using an Olympus IX70-FLA inverted fluorescence microscope. Images were taken using SPOT digital camera system (Diagnostic Instruments, Sterling Heights, Michigan, USA) and assembled with ImageJ software (Schneider et al. 2012) .
Microarray Analysis
This article has not been copyedited and formatted. The final version may differ from this version. GeneChip Terminal labeling system. Briefly, 100 ng of total RNA was used to start the first strand cDNA synthesis using an engineered random primer plus polyT7 promoter.
After the second strand cDNA synthesis, the antisense cRNA (in vitro transcription) was generated using T7 RNA polymerase. Then 10 μ g of cRNA was used to start the second cycle of cDNA synthesis using random primers plus dUTP and dNTP. The 
Statistical processing of microarray data
Microarray samples were RMA normalized (Irizarry et al. 2003) 
RESULTS
COH29 targets BRCA1-defective human cancer cells
Our previous data showed the broad antitumor activity of COH29 in the NCI-60 cell line panel, and that multiple human breast cancer cell lines as well as human ovarian cancer cell lines are sensitive to COH29 (Zhou et al. 2013 ). Breast and ovarian cancers occur with a greater frequency in carriers of a mutant BRCA1 gene than the general population (Wooster and Weber 2003) . We therefore investigated the activity of COH29
in several cell lines with differing BRCA1 status, including OV90 (BRCA1 wild-type), UWB1.289 (BRCA1-mutant), HCC1937 (BRCA1-mutant) and HCC1937+BRCA1 cells.
As shown in Fig. 1A (Fig.1B) . Likewise, similar results were observed in an isogenic pair of human breast cancer cell lines. HCC1937 cells were more sensitive to COH29 than their BRCA1 wild type expressing counterpart (HCC1937+BRCA1; Fig. 2A ). The sensitivity of BRCA1-deficient cells to COH29 was further tested in an orthotopic tumor explant model. The growth of HCC1937 tumors implanted into mouse mammary fat pads was significantly (47.0% p = 0.0007) suppressed by daily oral dosing with 400 mg/kg COH29 compared to vehicle by day 28 (Fig. 2B) . In contrast, growth of This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2C ). As the HCC1937+BRCA1 bearing animals were sacrificed per institutional guidelines at this time, no further comparisons between the effect of COH29 on the growth of the HCC1937 deficient xenografts and HCC1937+BRCA xenografts could be made. However, the HCC1937 xenografts were continued for a total of 60 days, in which the suppression of tumor growth by COH29 continued (data not shown).
The in vitro data indicated COH29 is more potent in BRCA1-defective cells. Among the IC 50 values shown in Table 1 , COH29 showed 4.8 times more potency in HCC1937 cells compared to HCC1937+BRCA1. Therefore we used these two cell lines in the subsequent experiments to investigate the cause of the differential sensitivity to COH29.
Effect of COH29 on DNA damage checkpoints
Next, we evaluated the effect of COH29 on DNA damage signaling in HCC1937 and HCC1937+BRCA1 cells. COH29 induced significant phosphorylation of checkpoint kinase proteins Chk1, Chk2, and increased the level of the DSB marker γ-H2AX in both cell lines (Fig. 3A) . Notably, COH29 triggered more obvious signaling in HCC1937 cells compared with HCC1937+BRCA1 cells in the same concentration range. A similar effect was also detected with HU treatment (Fig. 3B) . It has been reported that foxo3 is necessary for ATM-mediated apoptotic signaling after DNA damage (Chung et al. 2012 ).
As shown in Fig. 4A , induction of accumulation of p-ATM, γH2AX, foxo3, and its target protein p27 in the nucleus in response to COH29 was also observed. Furthermore, we
found that γH2AX and phospho-ATM colocalize with foxo3 in the nucleus by confocal This article has not been copyedited and formatted. The final version may differ from this version. immunofluorescence microscopy ( Fig. 4B and 4C ). These data suggest COH29
activates DNA damage signaling and recruitment of activated-ATM and foxo3 at DNA damage sites.
Differential gene expression in COH29 treated BRCA1-defective human breast cancer cells
We next performed genome-wide microarray analysis using the Affymetrix GeneChip microarray platform to identify the gene expression profiles and pathways affected by lesions is a well-documented step in the HR repair process to facilitate DNA damage repair (Deng and Brodie 2000) . Indeed, we detected obvious Rad51 foci formation in the nucleus in COH29-treated HCC1937/BRCA1 cells compared with COH29-treated HCC1937 cells (Fig. 5C ). Similar effects were also observed in HU-treated cells. Taken together, these data further support our hypothesis that BRCA1 may be the key player in determining the sensitivity of cancer cells to COH29.
Genotoxicity of COH29 in embryos of zebrafish
We next assessed the genotoxic effect of COH29 in wild-type zebrafish embryos treated from 1 to 7 dpf (day post-fertilization) with a range of doses of COH29 (0-100 μ M). HU (0-50 mM) was included as a positive control because it is known to cause developmental defects. As expected, HU caused defects in eyes and heart by 4 dpf This article has not been copyedited and formatted. The final version may differ from this version. 6A ) and resulted in a dose-dependent increase in the number of mutant embryos (Fig. 6B) . It is noteworthy that no developmental defects (Fig. 6C ) or decrease in viability ( Fig. 6D) were observed in the presence of COH29, indicating COH29 exhibits antitumor activity without causing genotoxicity.
DISCUSSION
In this study we sought to further define the biological effects of the novel RNR inhibitor COH29, which effectively inhibits proliferation of various cancer cell lines, especially ovarian cancer and leukemic cells, and overcomes resistance to the RNR inhibitor hydroxyurea (Zhou et al. 2013) . Building upon our initial observation that the BRCA1 deficient ovarian cancer cell line UWB1.289 was particularly sensitive to COH29
we determined BRCA1 status itself could account for this effect. Reconstitution of BRCA1 activity in the HCC1937 human breast cancer cell line, which expresses a truncated, inactive BRCA1 protein, (Tomlinson et al. 1998) in the stable transfectant clone HCC1937-BRCA1 blunted response to COH29 in vitro and in vivo. In addition, siRNA knockdown of BRCA1 increased sensitivity to COH29 in A2780 (BRCA1 wt) cells.
As shown in Supplemental Figure 1 , 72 h treatment with COH29 resulted in lower survival in A2780 cells transfected with BRCA1 siRNA than those transfected with control siRNA. These data suggested BRCA1 deficiency exaggerates the antiproliferative effect of COH29 treatment.
The signaling initiated by DNA damage is initially mediated by 'ataxiatelangiectasia-mutated' (ATM) and 'ATM and Rad3-related (ATR) kinases. The Chk1
and Chk2 DNA-damage-response kinases lie downstream of ATM and ATR (Abbas et al. 2013) . We observed that COH29 treatment led to more significant activation of ATM, Chk1, Chk2 and γH2AX in HCC1937 compared with HCC1937+BRCA1 cells. In addition, we found that γH2AX and phospho-ATM colocalize with foxo3 in the nucleus.
These data indicate COH29 triggers ATM-foxo3-γH2AX complexes at sites of DNA damage.
This article has not been copyedited and formatted. The final version may differ from this version. As BRCA1 is a critical mediator of cellular response to DNA damage and of HR repair, (Moeller et al. 2009 , Curtin 2012 this suggested that COH29 potency is modulated by the perturbed DNA repair pathways in BRCA1-deficient cells. Our observation that the GFP+ cell population was undetectable in HCC1937-DR-GFP cells suggested that HCC1937 cells are HR-deficient. When we investigated the effect of COH29 on the NHEJ repair pathway in HCC1937 cells using the EJ5-GFP reporter system we found that COH29 suppressed NHEJ repair efficiency (Fig. 5A ). Our microarray analysis (Table 2 ) also provided preliminary data in support of this, although further experiments covering a time course, and validation of identified genes would be needed to draw a strong conclusion. This is the subject of ongoing investigation.
In response to DNA damage, Rad51 translocates from the cytosol to the nucleus to form nucleofilaments on ssDNA, which is an essential step to promote the HR repair pathway (Haaf et al. 1995 , Baumann et al. 1996 . By confocal microscopy, we observed that COH29 induced significantly more γH2AX foci in HCC1937 cells compared with HCC1937+BRCA1 cells. In contrast, COH29 induced Rad51 nuclear foci in HCC1937+BRCA1 cells (Fig. 5C ), suggesting Rad51 has been recruited at damage sites to repair COH29-triggered DNA damage via the HR repair pathway in these BRCA1 wild-type cells. This effect of COH29 on Rad51 is similar to that documented for HU, which is known to stall replication forks (Petermann et al. 2010) , with the important distinction that COH29 is 20-fold more potent than HU (Zhou et al. 2013) , and is not appreciably genotoxic (Fig. 7) . Taken together, these results suggested inhibition of the NHEJ repair pathway by COH29 could also contribute to COH29-induced DSBs in HRdeficient HCC1937 cells.
This article has not been copyedited and formatted. The final version may differ from this version. The NHEJ pathway is reported as the major pathway for DNA repair of radiationinduced DSBs in mammalian cells (Riballo et al. 2004 ). Furthermore, a previous report has also proposed that quiescent/slowly cycling CSCs (Cancer Stem Cells) are more likely to use the error prone NHEJ pathway, resulting in offspring with enhanced chemoresistance and metastatic abilities after replication (Maugeri-Sacca et al. 2012 ).
This suggests that targeting the NHEJ pathway may be an effective way to kill cancer stem cells. Therefore, NHEJ inhibition may represent a potential strategy in patients with proficient NHEJ to increase the response to treatment.
However, the underlying mechanism of the effect of COH29 on DNA repair needs further evaluation. For instance, it is unclear whether this is a direct effect on the DNA repair machinery, or a consequence of depletion of dNTPs due to RNR inhibition.
There are a handful of reports which indicate that other RNR inhibitors also affect DNA repair pathways and or checkpoints. As mentioned above, the prototypic RNR inhibitor HU, causes upregulation of Rad51, and formation of both Rad51 and γ H2AX
foci. (Petermann et al. 2010 ) Gemcitabine, a nucleoside analogue that also inhibits the RNR large subunit (Shao et al. 2006) has been shown to be more potent in BRCA1 deficient cells, synergize with cisplatin, and induce Rad51 and γ H2AX foci. (Alli et al.
2011) Lin and colleagues knocked down RRM2 subunit expression and observed
results consistent with what we see for COH29, which is a specific RRM2 inhibitor (Zhou et al. 2013) ; activation of Chk1, and upregulation of γ H2AX. ) The same group have recently shown that the RRM1 inhibitor Triapine (3-AP, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone) caused Chk1 activation. (Lin et al. 2014 ).
TABLES
